03. 13. Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist

03. 13. Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzboll CG, Jorgensen A, Krintel SB, Raun J, Johansen JS, Ostergaard M, Stengaard-Pedersen K, OPERA study-group, Slot O, Nielsen LK, Skjodt H, Majgaard O, Lorenzen T, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H: Adalimumab added to a treat-to-target method with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis elevated remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2013, 73:65461. 14. Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M: A easy set of validation actions identifies and removes false final results in a sandwich enzyme-linked immunosorbent assay attributable to anti-animal IgG antibodies in plasma from arthritis patients. SpringerPlus 2013, two:263. 15. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R: Serum levels of CXCL13 are connected with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 2012, 14:R34. 16. Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH: Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model with the rheumatic joint. Arthritis Rheum 2011, 63:1265273. 17. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC: Prospective novel biomarkers of illness activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming development issue , tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating element. Arthritis Rheum 2008, 58:2257267. 18. Le Hir M, Bluethmann H, Kosco-Vilbois MH, Muller M, di Padova F, Moore M, Ryffel B, Eugster HP: Tumor necrosis factor receptor-1 signaling is expected for differentiation of follicular dendritic cells, germinal center formation, and complete antibody responses. J Inflamm 1995, 47:760. 19. Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, Chaplin DD: Signaling via TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13/CCL19/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells in to the B cell follicle.Vorapaxar J Immunol 2001, 167:1920928.Elagolix sodium 20.PMID:23983589 Wang Y, Wang J, Sun Y, Wu Q, Fu YX: Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells. J Immunol 2001, 166:33037.doi:10.1186/s13075-014-0434-z Cite this short article as: Greisen et al.: CXCL13 predicts illness activity in early rheumatoid arthritis and may be an indicator of your therapeutic `window of opportunity’. Arthritis Study Therapy 2014 16:434.Submit your subsequent manuscript to BioMed Central and take full benefit of:Convenient on the net submission Thorough peer overview No space constraints or colour figure charges Instant publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Study which is freely out there for redistributionSubmit your manuscript at www.biomedcentral/submit
JOURNAL OF WOMEN’S Well being Volume 22, Number five, 2013 Mary Ann Liebert, Inc. DOI: ten.1089/jwh.2012.Constructive Association Amongst 25-Hydroxyvitamin D and C-Reacti.